These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2682510)

  • 1. The use of aztreonam in the cystic fibrosis patient.
    Matsen JM; Bosso JA
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S117-9; discussion S128-32. PubMed ID: 2682510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG
    Pediatr Infect Dis J; 1988 Mar; 7(3):171-6. PubMed ID: 3128767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
    Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
    Allen JE; Bosso JA; Saxon BA; Matsen JM
    Diagn Microbiol Infect Dis; 1987 Sep; 8(1):51-5. PubMed ID: 3126018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG; Matsen JM
    Pediatr Infect Dis J; 1987 Apr; 6(4):393-7. PubMed ID: 3588112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aztreonam lysine for inhalation solution: in cystic fibrosis.
    Plosker GL
    Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled aztreonam.
    O'Sullivan BP; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 May; 9(5):357-8. PubMed ID: 20431562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of aztreonam in patients with cystic fibrosis and allergy to beta-lactam antibiotics.
    Jensen T; Pedersen SS; Høiby N; Koch C
    Rev Infect Dis; 1991; 13 Suppl 7():S594-7. PubMed ID: 2068465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Scully BE; Ores CN; Prince AS; Neu HC
    Rev Infect Dis; 1985; 7 Suppl 4():S669-74. PubMed ID: 3909322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam lysine for inhalation: new formulation of an old antibiotic.
    Zeitler K; Salvas B; Stevens V; Brown J
    Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Keating CL; Zuckerman JB; Singh PK; McKevitt M; Gurtovaya O; Bresnik M; Marshall BC; Saiman L
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
    Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S729-33. PubMed ID: 3909331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.